ArticleFrontiers in pharmacology2026
QT prolongation alerts lead to monitoring but rarely to therapeutic changes: a prospective hospital study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Drug-induced QT interval prolongation is a well-recognized safety concern in hospitalized patients. Clinical decision support systems (CDSS) generate alerts to identify high-risk drug combinations, but their impact on clinical management remains uncertain. Methods: This study evaluated clinical responses from prescribing clinicians to QT prolongation alerts, focusing on electrocardiogram (ECG) monitoring and treatment modifications. We conducted a 10-month prospective study in two hospital wards (acute geriatrics and orthopedics) at Geneva University Hospitals. The CDSS embedded within the electronic health record used a pharmacodynamic risk scoring system (Riskbase) that assigns scores to individual drugs based on pharmacological and clinical evidence and generates alerts when cumulative risk exceeds a predefined threshold. Clinical interventions were assessed within 7 days following high-risk QT alerts. Results: A total of 154 patients were included (123 in geriatrics and 31 in orthopedics). Intervention rates ranged from 60.2% to 91.9% in geriatrics and from 45.2% to 80.6% in orthopedics, depending on the time window. However, these interventions were almost exclusively driven by ECG monitoring. Treatment modifications were rare, occurring in only 2.0% of patients. Most alerts were associated with combinations of low- or moderate-risk drugs, particularly antipsychotics, antidepressants, and antiemetics, some of which may have alternatives with lower QT-prolongation potential and may be considered depending on the clinical context. In addition, medications prescribed on an as-needed basis contributed substantially to QT risk scores, despite limited recent administration. Discussion: In clinical practice, QT prolongation alerts are associated with frequent monitoring but rarely lead to therapeutic changes. These findings highlight a gap between risk identification and pharmacological risk mitigation and suggest opportunities to improve medication safety through more targeted prescribing and optimization of alert systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.